Trellus Health plc
TRLS:LN
Latest Coverage
Overview
Company Profile
Trellus Health is commercialising the provision of digital chronic condition management solutions for employers and health plans that utilise the scientifically validated GRITT™ resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate™ to coordinate and deliver care remotely via telemedicine. The Company is initially focused on Inflammatory Bowel Diseases (IBD), which include the chronic incurable conditions of Crohn’s Disease and ulcerative colitis, but considers its approach to have potential utility and demand across many chronic conditions.
The TrellusElevate™ platform is the Company’s proprietary connected health platform that incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five 5 years. The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85 per cent. reduction in unplanned healthcare utilisation (emergency department visits and hospitalisations) which the Directors believe indicates the potential for significant cost savings for healthcare payers.
The Company was formed in July 2020 as a UK incorporated company, with the exclusive license for commercialisation of the GRITT™ technology for IBD and seven broad disease categories granted by the Icahn School of Medicine at Mount Sinai (ISMMS).
Classification
Sector Healthcare
Industry Healthcare Providers & Services
Subindustry Healthcare Information Services
Financials
News & Media
Corporate
Board of Directors
Marla C. Dubinsky, MD
Co-Founder
Professor, Pediatrics, Gastroenterology, Chief of Division of Pediatric Gastroenterology, Co-Director Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Health; Co-Inventor of Prospect Tool; Co-Founder of Cornerstones Health
Salim Hamir, FCA
Chief Financial Officer and Co-Secretary
Board Secretary and Head of Corporate Affairs, EKF Diagnostics
Dr. Erik Lium, PhD
Non-Executive Director
Erik will represent ISMMS on the Board as part of the ongoing relationship between the Company and ISMMS. Erik is the President of Mount Sinai Innovation Partners and Executive Vice President and Chief Commercial Innovation Officer of Mount Sinai Health System, where he is responsible for advancing ISMMS’ research, instruction, and public service missions through strategic research partnerships with industry, the management, transfer and commercialisation of technologies, and fostering the development of start-ups and joint ventures to advance promising early-stage technologies and enhance ISMMS’ research and clinical enterprises. He is a Non-executive Director of Renalytix AI plc and is chair of their audit and remuneration committees and he is also a Non-executive Director of Verici Dx plc and is chair of their remuneration committee. Prior to joining ISMMS, Erik served as the Assistant Vice Chancellor of Innovation, Technology and Alliances at the University of California, San Francisco (UCSF), and the UCSF Principal Investigator for the Bay area National Science Foundation I-Corps node. Erik also previously served as a member of the Investment Review Committee for the Accelerate NY Seed Fund. He held previous positions at UCSF, including Assistant Vice Chancellor of Research and Director of Industry Contracts. Erik served as President of LabVelocity Inc., an Information Services Company focused on accelerating research and development in the life sciences, prior to its acquisition in 2004. He pursued post-doctoral research at UCSF in the laboratory of J. Michael Bishop, MD, and earned a PhD with honours from the Integrated Program in Cellular, Molecular and Biophysical Studies at Columbia University in the laboratory of Dr. Saul J. Silverstein. Erik holds a BS in Biology from Gonzaga University
Mike Salter
Non-Executive Director
Mike Salter is currently the Chief Executive officer of EKF Diagnostics Holdings plc. Previously, Mike worked at GE Healthcare where he was General Manager for the Custom Molecular Reagent Business within GE Life Sciences. He spent a total of 33 years with GE and Amersham in a variety of positions in the UK, Canada and USA.
Christopher Mills
Non-Executive Director
Christopher Mills founded Harwood Capital Management in 2011, a successor from its former parent company J.O. Hambro Capital Management (“Harwood”), which he co-founded in 1993. He is Chief Executive Officer and investment manager of North Atlantic Smaller Companies Investment Trust plc and Chairman and Chief Executive Officer of Harwood Capital Management Ltd. Prior to that, Mr. Mills was a Director of Invesco MIM, where he was head of North American Investments and Venture Capital, and of Samuel Montagu International. Mr. Mills currently serves on the board of a number of public companies, including EKF Diagnostics plc, RenalytixAI plc, Sureserve Group plc, Augean plc and MJ Gleeson plc. Mr. Mills received a B.A. in Business Studies from Guildhall University.
Julian Baines, MBE
Non-Executive Chairman
Julian is currently Non-Executive Chairman of Trellus Health plc and Verici Dx plc, as well as being Deputy Non-Executive Chairman of EKF Diagnostics Holdings plc. Julian has significant experience in the life science industry. He has over 20 years’ experience as CEO of EKF Diagnostics Holdings plc and BBI Holdings plc. Before joining EKF, he undertook a management buyout at BBI in 2000, a flotation on AIM in 2004 and was responsible for selling the business to Alere Inc. (now part of Abbott Laboratories) in 2008 for c. £85 million. At EKF he successfully completed a number of fund raisings, acquisitions and subsequent integration of businesses in seven countries. He oversaw the spin out of businesses from EKF including Renalytix plc which listed on Nasdaq in 2020. In 2016 he was awarded an MBE (Member of the British Empire) for services to the life sciences industry. Julian has previously held the position of Non-Executive Chairman of Renalytix Plc between 2018 and 2020.
Dan Mahony, PhD
Non-Executive Director
Co-Head Healthcare, Polar Capital Partners Board Member, Wellcome Sanger Institute, Celmatix, and Keepable Former Head of European Healthcare Research, Morgan Stanley Former Analyst, ING Barings Furman Selz Former Research Scientist, Schering Plough Corporation